Compounds useful as sfp booster agents
New compounds with formula (I) enhance sun protection and stabilize conventional UV filters, addressing the toxicity and stability issues of current sunscreens by reducing their use and improving skin appearance.
Patent Information
- Application Number
- PCT/EP2026/062943
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current sunscreens containing organic and/or inorganic filters are toxic to the environment and humans, non-biodegradable, and unstable under UV light, necessitating the development of new molecules that enhance sun protection while reducing the amount of conventional filters.
The use of new compounds with formula (I) that act as SPF boosters and antioxidants, enhancing the protective effect of conventional UV filters and stabilizing them, thereby reducing the amount of conventional filters required in formulations.
The new compounds provide enhanced sun protection and antioxidant benefits, improving skin homogeneity and reducing signs of aging while minimizing the use of potentially harmful conventional filters.
Smart Images

Figure EP2026062943_12112026_PF_FP_ABST
Abstract
Description
[0001] New compounds and uses in cosmetics
[0002] FIELD OF INVENTION
[0003] The present invention relates to the cosmetic field and in particular to new compounds and their uses, notably as an SPF booster agent.
[0004] STATE OF THE ART
[0005] It is known that daily exposure to ultraviolet (UV) rays, even of short duration and under normal conditions, can lead to skin browning and / or irregular pigmentation (e.g., brown spots, uneven skin tone), but also to a degradation of collagen and elastin fibers resulting in a change in the skin's microrelief and the appearance of signs of aging (e.g., wrinkles...).
[0006] Applying sunscreen daily is essential for preventing sunburn and protecting the skin from UVA / UVB rays. Numerous formulas designed for photoprotection (UV-A and / or UV-B) are now available, including water-soluble and / or oil-soluble organic UV filters and / or inorganic UV filters capable of selectively absorbing UV radiation. These filters (and their concentrations) are selected based on the desired Sun Protection Factor (SPF), which measures the level of protection against UVB rays. Choosing a sunscreen with the appropriate SPF also helps to enhance the appearance and longevity of your tan.
[0007] However, currently marketed sunscreens (also called reference UV filters or 'standard' UV filters, as described later) contain organic and / or inorganic filters that may be toxic to the environment and / or humans (e.g., endocrine disruptors). They are non-biodegradable and sometimes not very stable under UV light. Research into new molecules with UV activity is therefore crucial to reduce the amount of standard, and sometimes controversial, filters in formulas while maintaining good sun protection. These molecules can be natural or bio-based and can either boost sun protection or stabilize conventional filters to provide better long-term protection.
[0008] The Applicant has developed new formula compounds (I) and demonstrated their skin-protective activities. Specifically, it has shown that the use of these compounds enhances the protective effect provided by conventional organic and / or inorganic UV filters (also referred to as an 'SPF booster' effect) and consequently reduces the amount of conventional UV filters, some of which are controversial, in the formulation. It has also demonstrated an antioxidant effect for most of these formula compounds (I), beneficial for preventing and / or reducing the signs of skin aging.
[0009] DESCRIPTION OF THE INVENTION
[0010] The present invention therefore relates in particular to a cosmetic composition comprising, in a physiologically acceptable environment:
[0011] (i) A compound with the following formula (I):
[0012]
[0013] in which
[0014] R1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and
[0015] R 3 to R 7 independently represents H, a halogen, an OH group, an NO2 group, an N3 group, or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH, or N(Ci-Ce alkyl), or
[0016] R 2 and R 3 taken together they form a simple bond.
[0017] provided that when one among R 3 to R 7represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H,
[0018] in particular a compound of formula (I) as defined according to the invention in the paragraph 'new compounds of formula (I) according to the invention', and
[0019] (ii) One or more UV filter(s) selected from organic UV filters, inorganic UV filters, and mixtures thereof.
[0020] Another object of the invention relates to a cosmetic composition comprising, in a physiologically acceptable medium:
[0021] at least one compound of the following formula (I)R s (I)
[0022]
[0023] in which
[0024] R 1 and R 2independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-C6 alkyl), and
[0025] R 3 to R 7 represents independently of each other H, a halogen, an OH group, an NO2 group, an N3 group or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH or N(Ci-Ce alkyl),
[0026] Or
[0027] R 2 and R 3 taken together they form a simple bond.
[0028] provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R1 and R 2 is different from H, and
[0029] The compound with formula (I) is not one of the following compounds:
[0030]
[0031] or as defined in paragraph 'new compounds of formula (I) according to the invention'; and
[0032] an additional cosmetic ingredient. The present invention also relates to a compound of the following formula (I):
[0033]
[0034] in which
[0035] R 1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and
[0036] R 3 to R 7represents independently of each other H, a halogen, an OH group, an NO2 group, an N3 group or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH or N(Ci-Ce alkyl),
[0037] Or
[0038] R 2 and R 3 taken together they form a simple bond.
[0039] provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H, and
[0040] The compound with formula (I) is not one of the following compounds:
[0041]
[0042] By "cosmetic composition" we mean any composition intended for cosmetic purposes, that is to say aesthetic purposes, which may be brought into contact with the superficial parts of the human body and more particularly with keratinous materials, in particular human skin and / or lips.
[0043] By "physiologically acceptable medium" we mean any excipient suitable for topical use, in contact with keratinous materials, without risk of toxicity, incompatibility, instability and / or allergic response.
[0044] According to the invention, "keratinous materials" refers to skin and / or its appendages, and more particularly to human skin and / or lips. Specifically, this includes skin of the face, neck, and / or body, and lips. The keratinous materials in the context of the invention are healthy, that is, they do not exhibit any disorders or abnormalities indicative of a pathological condition (i.e., subjects who are "unhealthy" or suffering from a pathology). The terms "healthy skin" and / or "lips" will be used interchangeably throughout this description.
[0045] The invention also relates to a non-therapeutic cosmetic process for the care and / or makeup of healthy skin and / or healthy lips, comprising the application to said skin and / or said lips of a composition as defined according to the invention, in particular to improve the homogeneity of the complexion and / or reduce the signs of skin aging.
[0046] By 'improving the homogeneity of the complexion', we mean a luminous complexion with a homogeneous color, in particular a slightly tanned skin ('healthy glow') and without color irregularities.
[0047] By 'preventing and / or reducing the signs of skin aging', we mean reducing and / or slowing down the appearance of signs of skin aging and in particular the alteration of the biomechanical properties of the epidermis linked in particular to the degradation of collagen and elastin fibers.
[0048] Another object of the invention relates to the non-therapeutic use of a compound of formula (I) as defined in the paragraph 'new compounds of formula (I) according to the invention' or the paragraph 'compounds of formula (I) used according to the invention', in a cosmetic composition comprising one or more organic and / or inorganic UV filters, as an SPF booster. The present invention also relates to a compound of formula (I) as defined in the paragraph 'new compounds of formula (I) according to the invention' or the paragraph 'compounds of formula (I) used according to the invention', or to a composition comprising them, alone or in combination with one or more organic and / or inorganic UV filters, for use in the prevention and / or treatment of the adverse effects of ultraviolet radiation on the skin and / or lips. In particular, the composition prevents photoaging of the skin.
[0049] DETAILED DESCRIPTION OF THE INVENTION
[0050] Compounds of formula (I) used according to the invention
[0051] The Applicant has highlighted sun protection enhancement properties (SPF booster effect) and / or antioxidant properties for compounds of formula (I) as described below and therefore proposes to use them in compositions and uses according to the invention.
[0052] These include compounds with the following formula (I):
[0053]
[0054] in which
[0055] R 1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and
[0056] R 3 to R 7independently represents H, a halogen, an OH group, an NO2 group, an N3 group, or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH, or N(Ci-Ce alkyl), or
[0057] R 2 and R 3 taken together they form a simple bond.
[0058] provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H. Definitions
[0059] The term "aliphatic (C1-C12) chain" refers to a monovalent, saturated, linear or branched hydrocarbon chain comprising 1 to 12, in particular 1 to 6, carbon atoms. According to the invention, an aliphatic chain covers substituted or unsubstituted alkyl, alkenyl, or alkynyl groups, whether linear or branched.
[0060] The term "alkyl in (C x -C y ) », designates a monovalent saturated hydrocarbon chain, linear or branched, comprising x to y carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl groups.
[0061] The term "alkenyl en (C x -C y) » refers to a monovalent hydrocarbon chain, linear or branched, containing at least one double bond and comprising x to y carbon atoms. Examples include ethenyl, propenyl, allyl, butenyl, pentenyl, and hexenyl groups.
[0062] The term "alkynyl en (C x .C y ) » refers to a monovalent hydrocarbon chain, linear or branched, containing at least one triple bond and comprising x to y carbon atoms. Examples include ethynyl, propynyl, butynyl, pentynyl, or hexynyl groups.
[0063] The term "(Cx-Cy) alkoxy" refers to an (Cx-Cy) alkyl group, as defined above, linked to the rest of the molecule via an oxygen atom. Examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t-butoxy, n-pentoxy, and n-hexoxy.
[0064] The term "aryl" refers to an aromatic hydrocarbon group, preferably comprising 6 to 10 carbon atoms, and including one or more attached rings, such as a phenyl or naphthyl group.
[0065] The term "halogen" refers to the atoms of fluorine, chlorine, bromine, and iodine.
[0066] The term "optionally substituted" means that the group in question is optionally substituted by one or more substituents chosen from the group consisting of a halogen, a Ci-Ce alkyl, an aryl, OH, NH2, and COOH. 1 and R 2
[0067] In some embodiments, R 1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, in which one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O or C(O).
[0068] In some embodiments, R 1 and R 2 independently represent H or a C1-C20 alkyl, preferably H or a C1-Cs alkyl, more preferably H or a C1-C4 alkyl, for example a methyl or an ethyl, more particularly H or an ethyl. In some embodiments, R 1 and R 2 are identical.
[0069] In some embodiments, R 1 and R 2 both represent H. We will also refer to 'diacid' compounds according to the invention.
[0070] In other embodiments, R 1 and R 2 independently represent an alkyl group in Ci-Ce, for example a methyl or an ethyl group. In particular, R 1 and R 2 They both represent an ethyl group. They will also be referred to as 'diester' compounds according to the invention.
[0071] In other embodiments, R 1 and R2 are different. Thus, R 1 represents H and R 2 is an alkyl group in the form Ci-Ce, for example a methyl or an ethyl group, in particular an ethyl group. These will also be referred to as 'monoester' compounds according to the invention.
[0072] In some embodiments, R 2 and R 3 taken together form a simple bond. These compounds will also be referred to as 'cyclized' according to the invention.
[0073] In these embodiments, the compound of formula (I) comprises two fused rings and can be represented by the following formula (lA):
[0074]
[0075] In some embodiments, the compound of formula (lA) comprises a substituent R1 selected from H and a C1-C20 alkyl, preferably from H and a Ci-Cs alkyl, more preferably from H and a C1-C4 alkyl, for example a methyl or an ethyl, more particularly from H and an ethyl.
[0076] R 3to R 7
[0077] In some embodiments, R 3 to R 7 independently represent H, an OH group, or an optionally substituted C1-C12 aliphatic chain, in which one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O or C(O).
[0078] In some embodiments, R 3 to R 7 independently represent H, an OH group, a COOR' group with R' selected from H and a C1-C12 alkyl, a C1-C12 alkoxy, or a C1-C12 alkyl, preferably H, OH, a C1-C12 alkoxy, for example a methoxy or an ethoxy, or a C1-C12 alkyl, for example a methyl, an ethyl, or a tert-butyl. Preferably, R 3 to R 7 are each independently chosen from the group consisting of H, OH, a methoxy, a methyl and a tert-butyl.
[0079] In some embodiments, R 3 is H or, taken together with R 2 , forms a simple bond.
[0080] In some embodiments, R 4 is H or an OH group.
[0081] In some embodiments, R 5 is H or an OH group.
[0082] In some embodiments, R 6 is H, an OK group, or an alkyl in Ci-Ce, for example a methyl, an ethyl or a tert-butyl, preferably a methyl.
[0083] In some embodiments, R 7 is H.
[0084] In some embodiments, at least one of R 3 to R 7 is not H.
[0085] In some embodiments, two or three substitutes from among R 3 to R 7are not H and are as defined above, preferably chosen from OH, an alkoxy in Ci-Ce, for example a methoxy or an ethoxy, or an alkyl in Ci-Ce, for example a methyl or an ethyl, the remaining substituents from R 3 to R 7 representing H.
[0086] In some embodiments, when R 1 and R 2 both represent H, so preferably two or three substituents from R 3 to R 7 are not H and are preferably independently chosen from OH, an alkoxy in Ci-Ce, for example a methoxy or an ethoxy, or an alkyl in Ci-Ce, for example a methyl or an ethyl, the remaining substituents from R 3 to R 7 representing H.
[0087] In other embodiments, when R 1 and R 2 both represent H and only one substituent among R 3 to R 7does not represent H, this substituent is not OH and is preferentially chosen from an alkoxy in Ci-Ce, for example a methoxy or an ethoxy, or an alkyl in Ci-Ce, for example a methyl or an ethyl.
[0088] In some embodiments, the compound of formula (I) is chosen from the group consisting of:
[0089]
[0090]
[0091] In some embodiments, R 1 represents H or a C1-C20 alkyl, preferably H or a C1-Cs alkyl, more preferably H or a C1-C4 alkyl, for example a methyl or an ethyl, more particularly H or an ethyl; R 2 represents H or a C1-C20 alkyl, preferably H or a C1-Cs alkyl, more preferably H or a C1-C4 alkyl, for example a methyl or an ethyl, or, taken together with R 3 forms a simple bond; R 3 is H or, taken together with R 2, forms a simple bond; R 4 is H or an OH group; R 5 is H or an OH group; R 6 is H, an OH group, or a Ci-Ce alkyl group, for example a methyl, an ethyl, or a tert-butyl, preferably a methyl; and R 7 is H.
[0092] In some preferred embodiments, the compound of formula (I) is chosen from the group consisting of:
[0093]
[0094] New formula ingredients according to the invention
[0095] The present invention also relates to a compound of the following formula (I):
[0096]
[0097] in which
[0098] R 1 and R 2independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and
[0099] R 3 to R 7 independently represents H, a halogen, an OH group, an NO2 group, an N3 group, or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH, or N(Ci-Ce alkyl), or
[0100] R 2 and R 3 taken together they form a simple bond.
[0101] provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R 1 and R2 is different from H, and
[0102] The compound with formula (I) is not one of the following compounds:
[0103]
[0104] In some embodiments, R 2 and R 3 taken together form a simple bond. In these embodiments, the substitute R 1 is preferably chosen from H and a C1-C20 alkyl, preferably from H and a Ci-Cs alkyl, for example a methyl or an ethyl, more particularly R 1 is H. In these embodiments, two or three, in particular two, are substitutes among R 4 to R 7 are not H and are as defined above, preferably chosen from among OH, an alkoxy in C1-C2, for example a methoxy or an ethoxy, and an alkyl in C1-C6, for example a methyl or an ethyl, the remaining substituents from among R 4 to R 7 representing H. Preferably, two substitutes from R 4 to R 7represent OH, the remaining substituents among R 4 to R 7 representing H.
[0105] In some embodiments, R 1 and R 2 both represent H, and two or three, in particular two, are substituents among R 3 to R 7 are such as defined above and preferably independently chosen from OH, an alkoxy in Ci-Ce, for example a methoxy or an ethoxy, or an alkyl in Ci-Ce, for example a methyl or an ethyl, the remaining substituents from R 3 to R 7 representing H. In these embodiments, the two or three substituents among R 3 to R 7 not being H, they are different from each other.
[0106] Preferably, one out of R 3 to R 7 is OH and another among R 3 to R 7 is an alkyl in Ci-Ce, for example a methyl or an ethyl, the substituents remaining among R 3 to R 7 representing H.
[0107] In other embodiments, R 1 and R 2 both independently represent an alkyl group in Ci-Ce, specifically a methyl or an ethyl group. Preferably, R 1 and R 2 are identical and both represent an ethyl. In these embodiments, R 3 to R 7 are such as defined above and preferably, at least one, in particular one, among R 3 to R 7 is chosen from OH, an alkoxy in Ci-Ce, for example a methoxy or an ethoxy, or an alkyl in Ci-Ce, for example a methyl or an ethyl, the remaining substituents from R 3 to R 7 representing H. Preferably, one from R 3 to R 7 is OH, the remaining substituents among R 3 to R 7 representing H.
[0108] In some embodiments, the compound of formula (I) is chosen from the group consisting of:
[0109]
[0110]
[0111] In some embodiments, R 1 represents H or a C1-C20 alkyl, preferably H or a C1-Cs alkyl, more preferably H or a C1-C4 alkyl, for example a methyl or an ethyl, more particularly H or an ethyl; R 2 represents H or a C1-C20 alkyl, preferably H or a C1-Cs alkyl, more preferably H or a C1-C4 alkyl, for example a methyl or an ethyl, or, taken together with R 3 forms a simple bond; R 3 is H or, taken together with R 2 , forms a simple bond; R 4 is H or an OH group; R 5 is H or an OH group; R 6 is H, an OH group, or a Ci-Ce alkyl group, for example a methyl, an ethyl, or a tert-butyl, preferably a methyl; and R 7 is H; R 4 and R 5 not being simultaneously an OH and R group 5 and R 6not simultaneously being an OH group.
[0112] In some preferred embodiments, the compound of formula (I) is chosen from the group consisting of:
[0113]
[0114] Process for preparing compounds of formula (I)
[0115] The free and cyclized diacid compounds of the invention can be synthesized according to methods known to those skilled in the art, as described in Peet NP and Sunder S. (A reinvestigation of the synthesis of 1,2-dihydro[1,2]diazepin-3-one from pyrones, Heterocyles, 1986, 24(2), 394-399), in particular according to the following synthesis scheme:
[0116] 1 H2SO4 / T,A-70 Ô C HOOC ™ . «►
[0117]
[0118] 2h - 48h If necessary, the synthesis may include a subsequent esterification step to obtain a compound of formula (I) in which R 1 and / or R 2is different from H. This esterification step can be carried out using methods well known to those skilled in the art. In a particular embodiment, when R 1 and R 2 are identical and different from H, or when the compound of formula (I) is cyclized and corresponds to formula (IA) as defined above, the esterification step can be carried out according to a process such as that schematized below:
[0119]
[0120] Compositions according to the invention
[0121] Another object of the invention is a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined above in the paragraph "new compounds of formula (I) according to the invention" and an additional cosmetic ingredient.
[0122] The term 'additional cosmetic ingredient' refers in particular to a cosmetic ingredient selected from glycols, C2-C5 monoalcohols, oils, fatty esters, fatty acids, dispersants, emulsifiers, gelling agents, film-forming agents, fillers, colouring materials, including pigments, antioxidants, organic and / or inorganic UV filters, perfumes, preservatives, cosmetic actives, and mixtures thereof.
[0123] In a particular method, the additional cosmetic ingredient is a UV filter chosen from among organic UV filters, inorganic UV filters and their mixtures.
[0124] Thus, another object of the invention is a composition of the invention which will comprise, in a physiologically acceptable environment:
[0125] (i) A compound with the following formula (I):
[0126] R> ( |)
[0127]
[0128] in which
[0129] R 1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and
[0130] R 3 to R 7 independently represents H, a halogen, an OH group, an NO2 group, an N3 group, or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH, or N(Ci-Ce alkyl), or
[0131] R 2 and R 3 taken together form a simple link, provided that when one of R 3 to R 7represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H,
[0132] in particular a compound of formula (I) as defined above in the paragraph "Compounds of formula (I) used according to the invention" or a compound of formula (I) as defined above in the paragraph "New compounds of formula (I) according to the invention", and
[0133] (ii) One or more UV filter(s) selected from organic UV filters, inorganic UV filters, and mixtures thereof.
[0134] The content of compound of formula (I) will range in particular from 0.3 to 20%, in particular from 0.5 to 10% by weight in relation to the total weight of the composition.
[0135] Organic UV filters
[0136] Organic UV filters can be chosen from among lipophilic organic UV filters, water-soluble organic UV filters, and mixtures thereof.
[0137] By "organic liposoluble or lipophilic UV filter" we mean any organic compound that filters UV radiation, capable of being completely dissolved in molecular form or miscible in a liquid oil phase or of being solubilized in colloidal form (for example in micellar form) in a liquid oil phase.
[0138] A "water-soluble or hydrophilic organic UV filter" refers to any organic compound that filters UV radiation and is capable of being completely dissolved at the molecular level or miscible in a liquid aqueous phase, or of being solubilized in colloidal form (e.g., micellar water) in a liquid aqueous phase. A person skilled in the art will adjust the pH according to the hydrophilic UV filter used, remaining within pH ranges suitable for topical application to the skin and / or lips, for example, pH 6 to 9.
[0139] According to a particular embodiment, the composition according to the invention includes, in particular, at least one organic UVB filter. It may further include at least one organic UVA filter.
[0140] By "organic UVB filter", we mean any organic chemical molecule capable of exclusively absorbing UVB radiation in the wavelength range between 280 and 320 nm. By "organic UVA filter", we mean any organic chemical molecule capable of absorbing at least UVA radiation in the wavelength range between 320 and 400 nm; said molecule also being able to absorb UVB radiation in the wavelength range between 280 and 320 nm.
[0141] UV filters
[0142]
[0143] According to a particular mode, the composition of the invention comprises at least one lipophilic organic UV filter.
[0144] In particular, the composition will include one, two, or three lipophilic organic UV filters.
[0145] Lipophilic organic UV filters are chosen from among cinnamic derivatives; salicylic derivatives; dibenzoylmethane derivatives; benzophenone derivatives; p,p-diphenylacrylate derivatives; triazine derivatives, and mixtures thereof. Other examples include anthranilates; camphor derivatives; benzotriazole derivatives; benzalmalonate derivatives; imidazolines; p-aminobenzoic acid (PABA) derivatives; benzoxazole derivatives; filter polymers and silicone filters; α-alkylstyrene derivative dimers; 4,4-diarylbutadiene; and merocyanin derivatives and mixtures thereof.
[0146] According to a particular and preferred mode, the composition according to the invention comprises one or more lipophilic organic UV filters selected from the group consisting of cinnamyl derivatives; salicyl derivatives, dibenzoylmethane derivatives, benzophenone derivatives; p,p-diphenylacrylate derivatives; triazine derivatives, and mixtures thereof.
[0147] Lipophilic organic UVB filters are notably chosen from
[0148] p,p-diphenylacrylate or α-cyano-p,p-diphenylacrylate derivatives
[0149] salicylic derivatives
[0150] cinnamyl derivatives
[0151] triazine derivatives filtering only UVB radiation;
[0152] and their mixtures.
[0153] The lipophilic organic UVA filters according to the invention are in particular selected from:
[0154] dibenzoylmethane derivatives
[0155] benzophenone derivatives,
[0156] and their mixtures. Thus, the composition of the invention shall comprise at least one compound of formula (I) as defined previously in the chapters "compounds of formula (I) used according to the invention" or "new compounds of formula (I) according to the invention" and at least one organic UV filter, preferably at least one lipophilic organic UV filter.
[0157] According to a particular mode, the composition of the invention comprises at least one lipophilic organic UVB filter and optionally in addition at least one lipophilic organic UVA filter.
[0158] Thus, according to a particular mode, the composition of the invention shall comprise at least one compound of formula (I) as defined previously in the chapters "compounds of formula (I) used according to the invention" or "new compounds of formula (I) according to the invention" and at least one lipophilic organic UVB filter chosen in particular from p,p-diphenylacrylate derivatives, salicylic derivatives, cinnamic derivatives, triazine derivatives and mixtures thereof, and possibly in addition at least one lipophilic organic UVA filter chosen in particular from dibenzoylmethane derivatives, benzophenone derivatives, and mixtures thereof.
[0159] Examples of lipophilic organic UV filters include those listed below by their INCI names:
[0160] Cinnamic derivatives
[0161] Ethylhexyl Methoxycinnamate, also known as Octoxinate or Octyl Methoxicinnamate, is sold under the trade name "PARSOL MCX ®" by DSM Nutritional Products or ASHLAND.
[0162] Isopropyl Methoxycinnamate
[0163] Isoamyl p-Methoxycinnamate sold under the trade name NEO HELIOPAN E 1000 ® by Symrise
[0164] DEA Methoxycinnamate
[0165] Diisopropyl Methylcinnamate
[0166] Glyceryl Ethylhexanoate Dimethoxycinnamate.
[0167] Salicylic derivatives
[0168] Homosalate is sold under the name "Eusolex HMS®" by Rona / EM Industries, or under the name "Parsol HMS" by DSM.
[0169] Ethylhexyl Salicylate (EHS) sold under the name "NEO HELIOPAN OS®" by Symrise, or under the name "ESCALOL 587" by ASHLAND
[0170] Dipropylene glycol salicylate, sold under the name "DIPSAL®" by SCHER, TEA salicylate, sold under the name "NEO HELIOPAN TS®" by Symrise
[0171] Derivatives of di
[0172]
[0173] Butyl Methoxydibenzoylmethane or Avobenzone or BMDBM sold notably under the trade name "PARSOL 1789®" by DSM Nutritional Products, Inc or by Symrise;
[0174]
[0175] β-diphenylacrylate
[0176] Octocrylene is sold under the trade name "UVINUL N 539®" by BASF, or under the trade name "EUSOLEX OCR" by MERCK.
[0177] Etocrylene, sold notably under the trade name "UVINUL N 35®" by BASF.
[0178] Benzophenone derivatives
[0179] Benzophenone-1 sold under the trade name "UVINUL 400®" by BASF, Benzophenone-2 sold under the trade name "UVINUL D 50®" by BASF, Benzophenone-3 or Oxybenzone, sold under the trade name "UVINUL M 40®" by BASF,
[0180] Benzophenone-4 sold under the trade name "UVINUL MS 40®" by BASF, Benzophenone-5
[0181] Benzophenone-6 sold under the trade name "Helisorb 11®" by Norquay; Benzophenone-8 sold under the trade name "Spectra-Sorb UV-24®" by American Cyanamide
[0182] Benzophenone-9 sold under the trade name "UVINUL DS 49®" by BASF, Benzophenone-12
[0183] n-Hexyl 2-(4-diethylamino-2-hydroxybenzoyl)-benzoate or DHHB sold under the trade name "UVINUL A Plus ®", under the name "UVINUL A Plus Granular®", or in a mixture with octylmethoxycinnamate under the trade name "UVINUL A Plus B®" by BASF,
[0184] 1,1'-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]phenyl]-methanone (CAS 919803-06-8) as described in application W02007 / 071584; this compound being advantageously used in micronized form (average size of 0.02 to 2 pm) which can be obtained for example by the micronization process described in applications GB-A-2303 549 and EP-A-893119 and in particular in aqueous dispersion form.
[0185] Triazine derivatives
[0186] - Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine or BEMT or Bemotrizinol, sold under the trade name "TINOSORB S®" by BASF, - Ethylhexyl Triazone (abbreviation EHT) sold notably under the trade name "UVINIIL T150®" by BASF,
[0187] - Diethylhexyl Butamido Triazone sold under the trade name "UVASORB HEB®" by SIGMA 3V,
[0188] - 2,4,6-tris(4'-amino dineopentyl benzalmalonate)-s-triazine,
[0189] - 2,4,6-tris-(4’-amino benzalmalonate de diisobutyle)-s- triazine,
[0190] - 2,4-bis (4’-aminobenzoate de n-butyle)-6-(aminopropyltrisiloxane)-s-triazine,
[0191] - 2,4-bis (4’-aminobenzalmalonate de dinéopentyle)-6-(4’-aminobenzoate de n-butyle)-s-triazine,
[0192] - Symmetrical triazine filters substituted with naphthalenyl or polyphenyl groups described in US patent 6,225,467, application W02004 / 085412 (see compounds 6 and 9) or the document "Symetrical Triazine Derivatives" IP.COM IPCOM000031257 Journal, INC WEST HENRIETTA, NY, US (September 20, 2004), in particular 2,4,6-tris(di-phenyl)-triazine and 2,4,6-tris(ter-phenyl)-triazine, which is included in patent applications W006 / 035000, WO06 / 034982, W006 / 034991, W006 / 035007, W02006 / 034992, W02006 / 034985, these compounds being advantageously used in the form micronized (average particle size of 0.02 to 3 pm) which can be obtained for example according to the micronization process described in applications GB-A-2303549 and EP-A-893119 and in particular in aqueous dispersion;
[0193] - triazine silicones substituted by two aminobenzoate groups as described in patent EP0841341 in particular 2,4-bis-(n-butyl 4'-aminobenzalmalonate)-6-[(3-{1,3,3,3-tetramethyl-1-[(trimethylsilyloxy]disiloxanyl}propyl)amino]-s-triazine.
[0194] Other examples of lipophilic organic UV filters include:
[0195] Derivatives of para-aminobenzoic acid:
[0196] Ethyl PABA
[0197] Ethyl Dihydroxypropyl PABA
[0198] Ethylhexyl Dimethyl PABA, sold notably under the name "ESCALOL 507" by ISP.
[0199] Benzylidene camphor derivatives:
[0200] 3-Benzylidene camphor manufactured under the name "MEXORYL SD" by CHIMEX,
[0201] 4-Methylbenzylidene camphor sold under the name "EUSOLEX 6300" by MERCK, Polyacrylamidomethyl Benzylidene Camphor manufactured under the name "MEXORYL SW" by CHIMEX,
[0202] Phenylbenzotriazole derivatives:
[0203] Drometrizole Trisiloxane sold under the name "Silatrizole" by RHODIA CHIMIE, Derivatives
[0204]
[0205] Menthyl anthranilate sold under the trade name "NEO HELIOPAN MA" by SYMRISE,
[0206] Imidazoline derivatives:
[0207] Ethylhexyl Dimethoxybenzylidene Dioxoimidazoline Propionate,
[0208] Benzalmalonate derivatives:
[0209] Di-neopentyl 4'-methoxybenzalmalonate
[0210] Benzalmalonate-functionalized polyorganosiloxanes such as Polysilicone-15 sold under the trade name "PARSOL SLX" by DSM
[0211] 4,4-di derivatives
[0212]
[0213] 1,1-dicarboxy (2,2'-dimethyl-propyl)-4,4-diphenylbutadiene
[0214] Benzoxazole derivatives:
[0215] 2,4-bis-[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)-imino]-6-(2-ethylhexyl)-imino-1,3,5-triazine sold under the name Uvasorb K2A by Sigma 3V
[0216] and their mixtures.
[0217] Derivatives of
[0218]
[0219] - Octyl-5-N,N-diethylamino-2-phenysulfonyl-2,4-pentadienoate
[0220] and their mixtures.
[0221] Preferred organic filters are chosen from
[0222] Butyl Methoxydibenzoylmethane (BMDBM)
[0223] Ethylhexyl Methoxycinnamate or Octyl Methoxycinnamate or Octinoxate
[0224] Ethylhexyl Salicylate or Octylsalicylate,
[0225] Octocrylene
[0226] Homosalate or Homomenthyl salicylate
[0227] Benzophenone-3
[0228] Benzophenone-4
[0229] Diethyl amino Hydroxybenzoyl Hexyl Benzoate (DHHB),
[0230] Ethyl Hexyl triazone (EHT),
[0231] Bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), Drometrizole trixiloxane,
[0232] and their mixtures,
[0233] especially,
[0234] Butyl Methoxydibenzoylmethane (BMDBM)
[0235] Ethylhexyl Methoxycinnamate or Octyl Methoxycinnamate or Octinoxate
[0236] Octocrylene
[0237] Diethyl amino Hydroxybenzoyl Hexyl Benzoate (DHHB),
[0238] Ethyl Hexyl triazone (EHT),
[0239] Bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT),
[0240] and their mixtures.
[0241] Hydrophilic organic UV filters
[0242] The composition may further include one or more hydrophilic organic UV filters. For the purposes of this invention, a hydrophilic organic UV filter is defined as a water-soluble organic UV filter.
[0243] By "water-soluble organic filter" we mean any organic filter capable of being totally dissolved in molecular form in a liquid aqueous phase, or of being dissolved in colloidal form (for example in micellar form) in a liquid aqueous phase.
[0244] Examples of water-soluble organic UVB filters include water-soluble cinnamic derivatives such as ferulic acid or 3-methoxy-4-hydroxycinnamic acid; water-soluble benzylidene camphor compounds; water-soluble phenylbenzimidazole compounds; water-soluble p-aminobenzoic compounds (PABA); water-soluble salicylic compounds, and mixtures thereof.
[0245] In particular, we can cite phenyl benzimidazole compounds, such as 2-phenyl-1H-benzimidazole-5-sulfonic acid (INCI name: phenylbenzimidazole sulfonic acid) sold notably under the trade name "EUSOLEX 232®" by MERCK or "PARSOL® HS" by DSM.
[0246] Examples of water-soluble organic UVA filters include benzene 1,4-di(3-methylidene-10-camphosulfonic acid) (INCI name: Terephthalylidene Dicamphor Sulfonic Acid) and its various salts, described in particular in patent applications FR-A-2528420 and FR-A-2639347. Also noteworthy is benzene 1,4-di(3-methylidene-10-camphosulfonic acid) (INCI name: Terephthalylidene Dicamphor Sulfonic Acid) such as that manufactured under the name "MEXORYL® SX" by the company NOVEAL.According to a particular mode, the organic UV filters in the composition of the invention are selected from cinnamic derivatives; salicylic derivatives, dibenzoylmethane derivatives, benzophenone derivatives; p,p-diphenylacrylate derivatives; triazine derivatives, anthranilates; camphor derivatives; benzotriazole derivatives; benzalmalonate derivatives; imidazolines; p-aminobenzoic acid (PABA) derivatives; benzoxazole derivatives; α-alkylstyrene derivative dimers; 4,4-diarylbutadiene; merocyanine derivatives, merocyanins, phenyl benzimidazole compounds, Terephthalylidene Dicamphor Sulfonic Acid (TDSA), and mixtures thereof, and in particular:.
[0247] Lipophilic UVB filters are chosen from the group consisting of cinnamyl derivatives; salicylic derivatives; p,p-diphenylacrylate derivatives; triazine derivatives, phenyl benzotriazole derivatives, and mixtures thereof;
[0248] hydrophilic UVB filters are chosen from water-soluble phenylbenzimidazole compounds;
[0249] hydrophilic UVA filters such as terephthalylidene dicamphor sulfonic acid (TDSA), and
[0250] Lipophilic UVA filters are chosen from benzophenone derivatives, dibenzoylmethane derivatives, and mixtures thereof.
[0251] Thus, according to a particular method, the organic UV filter(s) used in the composition of the invention will be chosen from among, in particular, cinnamyl derivatives; p,p-diphenylacrylate derivatives; triazine derivatives, phenyl benzotriazole derivatives, benzophenone derivatives, dibenzoylmethane derivatives, and mixtures thereof, and preferably Butyl Methoxydibenzoylmethane (BMDBM), Ethylhexyl Methoxycinnamate or Octyl Methoxycinnamate or Octinoxate, Octocrylene, Diethyl amino Hydroxybenzoyl Hexyl Benzoate (DHHB), Ethyl Hexyl triazone (EHT), Bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT), and mixtures thereof.
[0252] Preferred examples of filter combinations are illustrated in the examples:
[0253] A dibenzoylmethane derivative and a cinnamic acid derivative, such as the combination Avobenzone (BMDBM - BUTYL METHOXYDI BENZOYLMETHANE) and Octinoxate or (Ethylhexyl Methoxycinnamate or Octyl methoxycinnamate),
[0254] A benzophenone derivative and a triazine derivative, such as the combination DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE (DHHB) and ETHYLHEXYL TRIAZONE EHT. A person skilled in the art will be able to choose the most suitable combinations of UV filters, depending on the formulation and the properties sought (protection against UVA and / or UVB).
[0255] Thus, according to a particular and preferred method, the composition includes at least:
[0256] a lipophilic organic UVB filter, in particular selected from cinnamic acid derivatives, p,p-diphenylacrylate derivatives, triazine derivatives, phenyl benzotriazole derivatives, and mixtures thereof
[0257] and advantageously in addition at least one additional organic UV filter, in particular chosen from among lipophilic organic UVA filters, such as a dibenzoylmethane derivative or a benzophenone derivative.
[0258] Inorganic UV filters
[0259] The inorganic UV filters used in the present invention are metal oxide pigments. In particular, the inorganic UV filters of the invention are metal oxide particles having an average elementary particle size less than or equal to 0.5 pm, more preferably between 0.1 and 0.5 pm, and even more preferably between 0.1 and 0.3 pm, or even 0.1 to 0.2 pm.
[0260] They are notably chosen from titanium oxides, zinc oxides, and their mixtures.
[0261] According to a particular embodiment of the invention, the inorganic UV filters are selected from the group consisting of zinc oxide, titanium dioxide and their mixture.
[0262] According to a particular mode, the composition of the invention comprises at least titanium dioxide.
[0263] Preferably, the titanium dioxide and zinc oxide particles used in the present invention are not nanometric particles, that is to say, they are not substances as defined in Article 3 of Regulation (EC) No 1907 / 2006, intentionally manufactured on the nanometric scale, containing particles, unbound or in aggregate or agglomerate form, of which a minimum proportion of the particles (50%), in the number size distribution, have one or more external dimensions between 1nm and 100nm.
[0264] Titanium dioxide (TiCh)
[0265] Titanium dioxide is usually in rutile form.
[0266] It may or may not be surface-treated.
[0267] In a particular method, titanium dioxide will be used on the surface with stearic acid, and preferably treated with alumina and stearic acid.
[0268] It can be presented as a powder or a dispersion. In powder form, one example is the Solaveil SpeXtra Titanium Dioxide Powder product line from CRODA, and in particular the Solaveil™ XTP-1 product, with the INCI name: Titanium Dioxide (and) Stearic Acid (and) Alumina. The average particle size is 179 nm, with over 99% of particles smaller than 300 nm and less than 5% smaller than 100 nm. It is therefore a non-nanoparticulate TiO2. Particle size measurement is performed using the Brookhaven X-Ray Disc Centrifuge (XRDC) technique to measure the particle size distribution of Solaveil SpeXtra powder dispersed in C12-C14 alkylbenzoate.
[0269] According to another embodiment, dispersions of TiO2 particles in an oily dispersant are used.
[0270] Examples include the Solaveil SpeXtra™ Dispersions product range, specifically the following references:
[0271] Solaveil™
[0272] Solaveil™
[0273] Solaveil™
[0274] According to a particular and preferred method, a TiO2 in powder form treated with a lipophilic agent is used, such as the reference Solaveil™ XTP-1 with INCI name: Titanium Dioxide (and) Stearic Acid (and) Alumina.
[0275] The TiO2 content, when present in the compositions of the invention, will generally range from 1 to 10% by weight relative to the total weight of the composition.
[0276]
[0277] zinc
[0278] Zinc oxide particles are usually in the form of a white powder.
[0279] The average size of the particles
[0280] One example is the commercial reference Zinc Oxide Gold Seal B from the company UNIVAR. The ZnO content, when present in the compositions of the invention, will generally range from 1 to 10% by weight relative to the total weight of the composition.
[0281] Dispersant
[0282] Metal oxide particles, in particular TiO2 and / or ZnO, are dispersed in a dispersant and / or wetting agent and ground, for example, with a three-roller mill.
[0283] Examples of dispersing and / or wetting agents include fatty acids such as stearic acid or hydroxystearic acid, fatty acid triglycerides such as caprylic / capric triglycerides, polyglycerol and fatty acid esters such as polyglyceryl-3 polyricinoleate, and mixtures thereof.
[0284] One example is the commercial reference APPLECARE PDS-300 MB with the NCI name: POLYHYDROXYSTEARIC ACID (and) CAPRYLIC / CAPRIC TRIGLYCERIDE (and) ISOSTEARIC ACID (and) LECITHIN (and) POLYGLYCERYL-3 POLYRICINOLEATE from the company DKSH.
[0285] According to a particular mode, the composition of the invention comprises at least one compound of formula (I) according to the invention, and titanium dioxide as an inorganic FUV.
[0286] According to another particular mode, the composition of the invention comprises at least one compound of formula (I) according to the invention, and zinc oxide as inorganic FUV.
[0287] Examples of combinations of compound of formula (I) according to the invention and organic and / or inorganic UV filters from different families (taken alone or in combination of 2) are described in the following table and represented by an 'x' (the symbol 7' corresponding to an untested condition), based on what has been illustrated in the examples below, without this being limiting:
[0288] Table 1
[0289] UV Filters Filter Association Association Compounds Compounds Organic or UV A of 2 B of 2 'mono- or 'diacids' 'cyclized' inorganic and single UV filters UV filters di-esters' according to according to compounds of according to the invention* the invention* formula (1) according to the invention*
[0290] the invention
[0291] Cinnamic acid derivative X / / / / (such as
[0292] octinoxate)**
[0293]
[0294] Derivative of p, p - X / / + + to ++ diphenylacrylate
[0295] (such as
[0296] octocrylene)**
[0297] X-derived dibenzoylmethane
[0298] (such as BMDBM or
[0299] avobenzone)**
[0300] Triazine derivative XX + ++++
[0301] (such as BEMT or
[0302] EHT)**
[0303] Derived from / / X / / / benzophenone (such as
[0304] than DHHB)**
[0305] 'Ester' compounds / + + + / / / according to the invention*
[0306] Compounds / / / / 'diacids'
[0307] according to the invention*
[0308] 'Cyclized' compounds
[0309] according to the invention*
[0310] TiO2 / / / ++ ++ + ZnO / / / ++++ ++++ /
[0311]
[0312] *as described in the paragraphs 'compounds of formula (I) used according to the invention' and preferably 'new compounds of formula (I) according to the invention' and in particular the following compounds illustrated in the examples, namely:
[0313] Two examples of ester (diester) compounds:
[0314] diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate
[0315]
[0316] OH
[0317] and diethyl(Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioate
[0318]
[0319] An example of a diacid compound: (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid
[0320]
[0321] - two examples of cyclized compounds: 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0322] and 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0323]
[0324] **as described in the 'Organic UV Filters' sections and in particular the following UV filters illustrated in the examples:
[0325] Octinoxate or Ethylhexyl Methoxycinnamate or Octyl methoxycinnamate or PARSOL MCX® - DSM Nutritial Products or ASHLAND ('Cinnamic acid derivative'), - Octocrylene - EUSOLEX OCR - MERCK ('p,-diphenyl acrylate derivative'), - Avobenzone or BMDBM - BUTYL METHOXYDIBENZOYLMETHANE- SYMRISE or DSM ('Dibenzoylmethane derivative'),
[0326] - BEMT - BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE - BEMOTRIZINOL ('Triazine derivative'), EHT or ETHYLHEXYL TRIAZONE - UVINUL T 150 ('Triazine derivative'), and DHHB or DI ETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE - UVINUL A PLUS GRANULAR ('Benzophenone derivative').
[0327] This table can be read with several entries: online reading with the SPF booster effect evaluated for the association of a compound of formula (I) according to the invention with a single UV filter from each family; and column reading with the SPF booster effect evaluated for the association of a compound of formula (I) according to the invention with two UV filters from different families.
[0328] The booster effect of compound formula (I) in the combination 'compound formula (I) with one or more organic UV filters', is expressed as a % improvement in SPF compared to the control condition (without compound formula (I)).
[0329] The notations from '+ to ++++' represent:
[0330] +: SPF improvement (SPF booster effect) of 5 to 30%
[0331] ++: SPF improvement (SPF booster effect) of 31 to 70%
[0332] +++: SPF improvement (SPF booster effect) from 71% to 100%
[0333] ++++: SPF improvement (SPF booster effect) greater than 100%
[0334] Depending on the desired SPF and the SPF booster effect of said compound of formula (I) according to the invention, a person skilled in the art will thus be able to define the optimal combinations (type of compound of formula (I), nature and content of the UV filter or combination of UV filters).
[0335] The composition of the invention shall in particular have an SPF of at least 15, in particular of at least 20, or even of at least 30, of at least 40 and better of at least 50.
[0336] For skincare compositions, and especially sunscreen compositions, an SPF of 10 to 50 is preferable, particularly 10 to 30, and ideally 15 to 30. For makeup compositions, such as foundations, an SPF of 5 to 15 is preferable.
[0337] SPF is defined as the ratio between the amount of energy required to produce minimal erythema on skin protected by sunscreen and the amount of energy required to produce the same level of erythema on unprotected skin.
[0338] In a specific manner, the sun protection factor (SPF) is determined in vitro by a protocol based on the method described in the publication: Validation of an in vitro sun protection factor (SPF) method in blinded ring-testing. Pissavini, M., et al.. (2018), Int J Cosmet Sci, 40: 263-268. (https: / / doi.org / 10.1111 / ics.12459).
[0339] The plate is the material onto which the sun protection composition is applied. For this protocol, polymethyl methacrylate (PMMA) plates proved ideal.
[0340] As described in the examples below, each formula is applied to 3 PMMA HD6 (HelioScreen) sheets and 3 PMMA SB6 (HelioScreen) sheets, at a rate of 1.3 and 1.2 mg / cm². 2 respectively. The spreading is carried out using the HD-SpreadMaster robot (HelioScreen; the application probe being covered with a nitrile finger cot pre-saturated with product).
[0341] To measure a blank spectrum, one plate of each type was prepared with 15 pL of petrolatum. Absorbance measurements were performed using an OL756 spectroradiometer (OPTRONICS LABORATORIES). The in vitro FPS was then calculated using the following formula:
[0342] 400
[0343] f R / JW KJ **M / J
[0344] S omPFr* m * vi •t<-ro = 29 -0
[0345]
[0346] f Eu. nt zi io U ' t,u " d 'd / .
[0347] 290
[0348] in which
[0349] E(A) = erythemal action spectrum described by the CIE
[0350] I (A) = Global spectral irradiance at 40°N, midday, mid-summer;
[0351] dÀ = No measurement (1nm)
[0352] Initial â(z) = CHDC» 1HIM(Z) + CSB6ASBÔ(Â)
[0353] with
[0354] CHD6 = 0.225
[0355] CSB6 = 0.800
[0356] The evaluation of the Sun Protection Factor (SPF) of compositions can also be carried out in-vivo according to the ISO / EN 24444 protocol "Cosmetics-Sun protection test methods-In-vivo determination of the sun protection factor (SPF) (2010)".
[0357] A person skilled in the art will adjust accordingly the respective contents of organic and / or inorganic UV filters and of compound of formula (I) as defined previously in the chapters "Compounds of formula (I) used according to the invention" or "New compounds of formula (I) according to the invention," to achieve this SPF protection performance. Thanks to the SPF-boosting effect of compounds of formula (I) as defined previously in the chapters "Compounds of formula (I) used according to the invention" or "New compounds of formula (I) according to the invention," it is advantageous to reduce the contents of conventional UV filters, some of which are controversial, in favor of new compounds.
[0358] The total organic and / or inorganic UFO content will generally range from 0.3 to 20% by weight, specifically from 0.5 to 15% by weight relative to the total weight of the composition.
[0359] Thus, for a skincare composition, particularly a sunscreen, the total content of organic and / or inorganic FUVs will generally range from 0.3 to 20% by weight, specifically from 0.5 to 15% by weight relative to the total weight of the composition.
[0360] And the content of compound formula (I) will generally range from 0.3 to 20% by weight, specifically from 0.5 to 10% by weight relative to the total weight of the composition
[0361] Thus, for a makeup composition, particularly foundation, the total content of organic and / or inorganic UVFs will generally range from 0.5 to 15% by weight, specifically from 1 to 10% by weight relative to the total weight of the composition.
[0362] And the content of compound formula (I) will generally range from 0.3 to 20% by weight, specifically from 0.5 to 10% by weight relative to the total weight of the composition
[0363] Oily phase
[0364] The composition of the invention will generally include at least one oily phase.
[0365] The term "oily phase" refers to an oil or a mixture of miscible oils. "Oil" is defined as a fatty substance, insoluble in water, and liquid at 25°C and atmospheric pressure.
[0366] The oils can be chosen from hydrocarbon oils, silicone oils and their mixtures.
[0367] According to the invention, "hydrocarbon oil" means an oil containing mainly hydrogen and carbon atoms.
[0368] According to the invention, "siliconized oil" means an oil comprising at least one silicon atom, and in particular at least one Si-O group.
[0369] Preferably, hydrocarbon oils should be used.
[0370] Examples include linear or branched C8-C19 alkanes, oils selected from vegetable hydrocarbon oils, synthetic C10-C40 ethers, synthetic C10-C40 esters, fatty C12-C26 alcohols, higher C12-C22 fatty acids, and mixtures thereof.
[0371] In a particular manner, the composition will include at least one ester oil.
[0372] Among the "ester oils" (polar), we can notably mention:
[0373] - hydroxylated esters, preferably having a total number of carbons from 35 to 70, such as polyglycerol-2 triisostearate, isostearyl lactate, octyldodecyl hydroxystearate, diisostearyl malate, propyl gallate; glycerin stearate; diethylene glycol diisononanoate;
[0374] - fatty acid esters, in particular those with 4 to 22 carbon atoms,
[0375] - synthetic esters such as oils with the formula R1COOR2, in which Ri represents the remainder of a linear or branched fatty acid containing 4 to 40 carbon atoms and R2 represents a hydrocarbon chain, particularly a branched one, containing 4 to 40 carbon atoms, provided that R1+R2 is >16, such as isononyl isononanoate, ethyl 2-hexyl palmitate, octyldodecyl neopentanoate, octyl-2-dodecyl stearate, isostearyl isostearate, octyl-2-dodecyl benzoate, isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, 2-ethylhexyl palmitate, 2-hexyldecyl laurate, palmitate 2-Octyl-decyl, 2-Octyldodecyl myristate, 2-Diethyl-hexyl succinate;
[0376] - linear fatty acid esters having a total number of carbons ranging from 35 to 70;
[0377] - esters of aromatic acids and alcohols comprising 4 to 22 atoms;
[0378] - esters of fatty alcohols or C24-C28 branched fatty acids;
[0379] - polyesters resulting from the esterification of at least one hydroxylated carboxylic acid(s) triglyceride by an aliphatic monocarboxylic acid and by an aliphatic dicarboxylic acid, possibly unsaturated;
[0380] and their mixtures.
[0381] The oily phase of the composition according to the invention shall generally represent 20 to 55% by weight, preferably 30 to 45% by weight relative to the total weight of said composition.
[0382] Aqueous phase
[0383] The composition of the invention generally also includes an aqueous phase.
[0384] The aqueous phase of the composition comprises water and possibly a water-soluble solvent.
[0385] The term 'water-soluble solvent' according to the invention means a compound that is liquid at room temperature and miscible with water (miscibility in water greater than 50% by weight at 25°C and atmospheric pressure). Examples include:
[0386] - lower C1-C5 monoalcohols such as ethanol, isopropanol and their mixtures, preferably ethanol;
[0387] - C2-C8 glycols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, pentylene glycol, dipropylene glycol, and mixtures thereof, preferably C3-C5 glycols; - C2-C32 polyols such as glycerol, polyglycerols, polyethylene glycols, and mixtures thereof,
[0388] and mixtures thereof. It may also include hydrophilic gelling agents, antioxidants, preservatives and mixtures thereof.
[0389] The aqueous phase of the composition according to the invention shall generally represent 45 to 80% by weight relative to the total weight of said composition, and preferably 55 to 70% by weight relative to the total weight of said composition.
[0390] Coloring agents
[0391] According to a particular embodiment of the invention, especially for tinted skincare or makeup compositions, the composition comprises at least one coloring agent. For the purposes of this invention, a coloring agent is understood to be a compound capable of producing a colored optical effect when formulated in sufficient quantity in a suitable cosmetic medium.
[0392] A coloring material can be chosen from organic or inorganic coloring materials, optical effect materials, and mixtures thereof, soluble or insoluble in the oily phase of the invention.
[0393] In a particular way, the coloring material(s) are pigments, notably chosen from mineral pigments, organic pigments, and their mixtures.
[0394] The term "pigments" refers to white or colored particles, mineral or organic, insoluble in aqueous solution, intended to color and / or opacify the resulting deposit. Depending on the specific method, the pigment(s) are chosen from among mineral and / or organic pigments, composite pigments (based on mineral and / or organic materials), mother-of-pearl or pearlescent pigments, and mixtures thereof.
[0395] Examples of "mineral pigments" include titanium dioxide (rutile or anatase), possibly surface-treated; black, yellow, red and brown iron oxides; manganese violet; ultramarine blue; chromium oxide; hydrated chromium oxide; and ferric blue.
[0396] Among the "organic pigments", we can cite, for example, the pigments D & C red no. 19; D & C red no. 9; D & C Red no. 22; D & C Red no. 21; D & C Red no. 28; D & C Yellow no. 6; D & C orange no. 4; D & C orange no. 5; D & C Red no. 27; D & C red no. 13; D & C Red no. 7; D & C Red no. 6; D & C Yellow no. 5; D & C Red no. 36; D & C Red no. 33; D & C orange no. 10; D & C yellow no. 6; D & C Red no. 30; D & C red no. 3; D & C Blue 1; carbon black and carmine-based lakes.
[0397] According to a particular mode, the composition of the invention comprises at least iron oxides.
[0398] When the composition includes coloring materials and in particular pigments, especially in the case of tinted skincare compositions or makeup compositions, their content will generally range from 0.1% to 25% by weight, preferably from 8% to 15% by weight relative to the total weight of the composition.
[0399] Pharmaceutical Formulations
[0400] The composition is preferentially intended to be applied to the skin and / or lips, in particular the skin of the face and / or body.
[0401] According to a particular mode, the composition of the invention is a skincare composition, a sun composition or a makeup composition for the skin and / or lips, in particular a skincare composition or a foundation.
[0402] According to the first method, it will be a composition for the care and / or sun protection of keratinous materials, in particular of the skin of the body or face, preferably the face.
[0403] In particular, a composition of the invention may be in the form of an anti-aging skincare composition for the body or face, especially the face. According to another embodiment, a composition of the invention may be in the form of a photoprotective composition, such as a sunscreen.
[0404] In another way, it will be a makeup composition for the skin of the face, in particular a foundation.
[0405] It can be presented in particular in the form of an emulsion, notably an oil-in-water emulsion or a water-in-oil emulsion, a lotion, an aqueous gel, a milk, an oil, a serum, a cream, or a balm.
[0406] According to a particular mode, the composition of the invention is in the form of a water-in-oil (W / O) emulsion.
[0407] In the case of skincare compositions, particularly sunscreens, this may include a cream, a lotion, an oil, a balm or a self-tanner.
[0408] In the case of makeup compositions, this may include, in particular, a foundation, a primer, or a lipstick.
[0409] METHOD AND USES
[0410] The invention also relates to a non-therapeutic cosmetic process for healthy skin and / or lips, comprising the application to said skin and / or lips of a composition as defined above, in particular to improve the evenness of skin tone and / or reduce the signs of skin aging. The keratinous materials (skin and / or lips) within the scope of the invention are healthy, that is to say, not exhibiting any disorders or abnormalities that would be indicative of a pathological condition (subjects "not healthy", suffering from a pathology).
[0411] According to a particular method, the non-therapeutic cosmetic process according to the invention aims to improve the homogeneity of the complexion.
[0412] By 'improving the evenness of the complexion', we mean a luminous and uniformly colored complexion, in particular a slightly tanned skin tone ('healthy glow') and without color irregularities. Alternatively, the non-therapeutic cosmetic process according to the invention aims to prevent and / or reduce the signs of skin aging.
[0413] By 'preventing and / or reducing the signs of skin aging', we mean reducing and / or slowing down the appearance of signs of skin aging and in particular the alteration of the biomechanical properties of the epidermis linked in particular to the degradation of collagen and elastin fibers.
[0414] According to a particular and preferred method, the composition of the invention is applied to the skin before and during exposure to sunlight to protect it against UV radiation.
[0415] According to another method, the composition of the invention is applied to the skin after exposure to sunlight to enhance the tan and bronze and improve its durability over time.
[0416] Another object of the invention relates to the non-therapeutic use of a compound of formula (I) as defined in paragraph 'new compounds of formula (I) according to the invention' or paragraph 'compounds of formula (I) used according to the invention', in a cosmetic composition comprising one or more organic and / or inorganic UV filters, as an SPF booster agent.
[0417] The Applicant has indeed shown that the use of a compound of formula (I) as defined in the paragraph 'new compounds of formula (I) according to the invention' or the paragraph 'compounds of formula (I) used according to the invention' makes it possible to boost the protective effect of organic and / or inorganic UVFs. This will also be referred to as an 'SPF booster' or 'sunscreen activator'. The presence of a compound of formula (I) as defined in the paragraph 'new compounds of formula (I) according to the invention' or the paragraph 'compounds of formula (I) used according to the invention' in the composition of the invention makes it possible to reduce the content of common UVFs, which are controversial for some, while maintaining protection (SPF).
[0418] The use of compound formula (I) according to the invention thus makes it possible to improve (also said to 'boost') the protection of keratinous materials against UV radiation. The examples illustrated below show that the composition according to the invention, comprising compound formula (I) according to the invention at a concentration of 2% by weight relative to the total weight of the composition, allows for an increase in SPF of at least 5%, in particular at least 10%, in particular at least 20%, preferably at least 30%, or even at least 40%, compared to the same composition without compound formula (I) according to the invention. In other words, the combination of compound formula (I) according to the invention, in particular at a concentration greater than or equal to 1% by weight, in particular greater than or equal to 2% by weight relative to the total weight of the composition, and organic UVF, has a synergistic effect on SPF protection.
[0419] This SPF booster effect of the compound of formula (I) according to the invention, thus makes it possible to reduce the content of common FUVs, which are controversial for some (non-biodegradable compounds).
[0420] The present invention also relates to a compound of formula (I) as defined in paragraph 'new compounds of formula (I) according to the invention' or paragraph 'compounds of formula (I) used according to the invention' or to a composition comprising them, alone or in association with one or more organic and / or inorganic UV filters, for use in the prevention and / or treatment of the adverse effects of ultraviolet radiation on the skin and / or lips.
[0421] In particular, the composition prevents photoaging of the skin.
[0422] The invention will now be illustrated in the following non-limiting examples. Unless otherwise stated, percentages are expressed as a percentage by weight of ingredient relative to the total weight of the composition.
[0423] EXAMPLES
[0424] Example 1: Synthesis of compounds of formula (I) according to the invention
[0425] The compounds of formula (I) according to the invention and used in the examples below were synthesized according to the following process:
[0426] Citric acid dissolved in 96% sulfuric acid is successively held at room temperature for 1 hour and then heated to 70°C for 30 minutes. The preparation is cooled to room temperature, and the aromatic compound is added. The mixture is held at room temperature for 2 to 48 hours and then poured onto ice-cold water. The resulting precipitate is filtered and purified by liquid-liquid extraction using a mixture of ethyl acetate and a saturated sodium bicarbonate solution.
[0427] Esterification:
[0428] The diacid or cyclized monoacid compound is dissolved in an alcohol, preferably ethanol. A catalytic amount of sulfuric acid is added. The reaction is carried out under reflux for 12 hours. The product is then isolated by liquid-liquid extraction or purified by chromatography.
[0429]
[0430] 2: Evaluation of their
[0431] 2-7 Absorbance spectra of compounds
[0432] The absorbance spectra of the compounds of formula (I) according to the invention were measured at 1.10' 5 M of each compound in ethanol, using an OL756 spectroradiometer (OPTRONICS LABORATORIES). The Applicant observed that:
[0433] Diacid compounds mainly absorb wavelengths between 260nm and 370nm (UVB-UVA);
[0434] Cyclic compounds mainly absorb wavelengths between 260nm and 330nm (UVB-UVA);
[0435] Ester compounds mainly absorb wavelengths between 260nm and 320nm (UVC-UVB).
[0436] 2-2 Evaluation of their SPF-boosting properties in combination with organic UV filters
[0437] Five compounds (two diester compounds, one diacid compound, and two cyclized compounds), representative of chemical subfamilies of formula (I) of the compounds of the invention, were evaluated in the same skincare formula, alone or in combination with various organic UV filters, to measure their SPF effect and their SPF-boosting effect (in combination with other organic UV filters). The compounds of formula (I) were tested at a concentration of 2% by weight relative to the total weight of the composition.
[0438] Compounds of formula (I) of the invention tested:
[0439] Two examples of diester compounds:
[0440] diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate
[0441]
[0442] OH
[0443] and diethyl(Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioate
[0444]
[0445] An example of a diacid compound: (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid
[0446]
[0447] OH
[0448] Two examples of cyclized compounds:
[0449] 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0450] OH
[0451] and 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0452]
[0453] Organic UV filters tested:
[0454] Octinoxate or Ethylhexyl Methoxycinnamate or Octyl methoxycinnamate or PARSOL MCX® - DSM Nutritial Products or ASHLAND ('Cinnamic acid derivative'), - Octocrylene - EUSOLEX OCR - MERCK ('p,-diphenyl acrylate derivative'), - Avobenzone or BMDBM - BUTYL METHOXYDIBENZOYLMETHANE- SYMRISE or DSM ('Dibenzoylmethane derivative'),
[0455] - BEMT - BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE - BEMOTRIZINOL ('Triazine derivative'), - EHT or ETHYLHEXYL TRIAZONE - UVINUL T 150 ('Triazine derivative'), and
[0456] - DHHB or DI ETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE - UVINUL A PLUS GRANULAR ('Benzophenone derivative').
[0457] Organic UV filters are tested at different concentrations, indicated in the results table.
[0458] The oil-in-water (O / W) skincare formula used in this study has the following composition:
[0459] Table 2
[0460] Phase Ingredients (INCI name and commercial reference) % by weight
[0461] A1 WATER Qsp 100
[0462] A1 GLYCERIN 5.0
[0463] A1 HYDROXYACETOPHENONE (SYMSAVE H) 0.3
[0464] A1 CHLORPHENESIN 0.27
[0465] A2 HYDROXYETHYL ACRYLATE / SODIUM 0.5
[0466] ACRYLOYLDIMETHYL TAU RATE COPOLYMER
[0467] and sorbitan isostearate and
[0468] POLYSORBATE 60 (SEPINOV EMT 10 MB)
[0469] B COCO-CAPRYLATE / CAPRATE (CETIOL LC MB) 5.0
[0470] B DIISOPROPYL SEBACATE (DUB DIS) 3.0
[0471] B BUTYLENE GLYCOL 3.0
[0472] DICAPRYLATE / DICAPRATE
[0473] B CETYL ALCOHOL 1.8
[0474] B STEARETH-21 1.5
[0475] B STEARETH-2 0.8
[0476] B ORGANIC UV FILTER(S) X
[0477] C COMPOSED BY FORMULA (I) Y
[0478]
[0479] The %X and Y values are shown in Table 3 of results below.
[0480] The tested organic filters and respectively the compounds of formula (I) of the invention are incorporated into the skincare formula according to the following protocol:
[0481] The ingredients of the oily phase B containing the reference UV filters are weighed in a beaker, then phase B is heated to 80°C using a water bath (for a period not exceeding 30 minutes so as not to denature the UV filters);
[0482] For aqueous phase A: phase A1 is heated to 80°C to solubilize chlorphenesin, then phase A2 is added under agitation U LTRATURRAX until no grains are present in the formula; Phase B is then added to phase A under ultraturrax at 80°C in a thin stream, then the mixture is left under agitation for 10 min at 3000 to 7 min to form the emulsion.
[0483] Phase C containing the compound of the invention is prepared using a magnetic stir bar, at room temperature for diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate, diethyl (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioate and respectively (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid, and by heating to 70°C for 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid and respectively 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid.
[0484] Then the prepared phase C is added after emulsification according to the following protocol:
[0485] For diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate, diethyl (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioate and respectively (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid, below 40°C, phase C is added, and left under stirring at 3000 rpm for 5 min;
[0486] for 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid and respectively 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid, at 70°C, phase C is added, and left under stirring at 3000 rpm for 5 min.
[0487] The compositions were then evaluated according to different criteria (SPF).
[0488] SPF / n vitro
[0489] The sun protection factor (SPF) is determined in vitro by a protocol based on the method described in the publication: Validation of an in vitro sun protection factor (SPF) method in blinded ring-testing. Pissavini, M., et al.. (2018), Int J Cosmet Sci, 40: 263-268. (https: / / doi.org / 10.1111 / ics.12459).
[0490] Each formula is applied to 3 PMMA HD6 (HelioScreen) plates and 3 PMMA SB6 (HelioScreen) plates, at a rate of 1.3 and 1.2 mg / cm². 2respectively. The spreading is carried out using the HD-SpreadMaster robot (HelioScreen; the application probe being covered with a nitrile finger cot pre-saturated with product).
[0491] To measure a blank spectrum, one plate of each type was prepared with 15 pL of petrolatum. Absorbance measurements were performed using an OL756 spectroradiometer (OPTRONICS LABORATORIES). The in vitro SPF was then calculated using the following formula:
[0492] 4 J00
[0493] h\À)l(A)uA
[0494] SPF in vitro = — — — — - 4(X)
[0495]
[0496] f
[0497] 290 in which
[0498] E(A) = erythemal action spectrum described by the CIE
[0499] l(A) = Global spectral irradiance at 40°N, midday, mid-summer;
[0500] dÀ = No measurement (1nm)
[0501] Initial A(Â) = CHD6A HD(3(A) + CSB6-ASB6(^-)
[0502] with
[0503] CHD6 = 0.225
[0504] CSB6 = 0.800
[0505] The SPF obtained corresponds to the 'SPF at T0' indicated in the table below.
[0506] Formulas 1 to 4 are the control skincare formulas, with organic UV filters, but without the compound of the invention.
[0507] Formulas 5, 10, 15, 20 and 25 are the care formulas with each of the compounds of the invention tested at 2% and allow the SPF effect of the compound as such to be measured.
[0508] Formulas 30 and 32 are the care formulas comprising the combination of the different organic UV filters with compounds of the invention tested at 1% and allow to measure the SPF booster effect of the compound of the invention.
[0509] Formula 31 is a skincare formula comprising the combination of various organic UV filters with a compound of the invention tested at 0.5% and allows the SPF booster effect of the compound of the invention to be measured.
[0510] The other formulas are the skincare formulas comprising the combination of the different organic UV filters with each of the compounds of the invention tested at 2% and allow to measure the SPF booster effect of the compound of the invention.
[0511] The SPF is evaluated at T0.
[0512] The SPF gain or SPF booster effect correlated to the presence of the compound of the invention in association with organic UV filters can also be calculated, expressed as a percentage increase in SPF and calculated as follows:
[0513] {((SPF value of organic UVFs with the compound of the invention) - (SPF value of organic UVFs without the compound of the invention)) / (SPF value of organic UVFs without the compound of the invention)} x 100.
[0514] The results obtained are presented in the following table, with:
[0515] 1 er Diester compound = diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate
[0516] 2 nd Diester compound = diethyl(Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioate Diacid compound = (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid er Cyclized compound = 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid nd Cyclized compound = 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0517] Table 3
[0518] 2nd Booster Effect 2nd SPF Compound at T0 Cyclized Compound Expressed as a % UV Filters 1st 1 er
[0519] Formulated with SPF increase in organic compounds.
[0520] s Compos T0 n of the SPF with reference é d lester é cyclisé
[0521] The diacid compound of the invention versus without 12.7 ± /
[0522] 1 BEMT at 10%
[0523] 0.3
[0524] 5% / Avobenzone 14.5 ±
[0525] 2
[0526] + 5% 0.5
[0527] Octinoxate
[0528] 10% 7.8 ± / 3
[0529] Octocrylene 0.3
[0530] 6% DHHB + 17.1 ± /
[0531] 4
[0532] 4% EHT 0.5
[0533] 2.6 ± /
[0534] 5 / 2%
[0535] 0.4
[0536] 16.3 ± + 28%
[0537] 6 10% BEMT 2%
[0538] 1.3
[0539] 5% + 50% Avobenzone 21.8 ±
[0540] 7.2%
[0541] + 5% 0.4
[0542] Octinoxate
[0543] 10% 9.6 + 23% 8 2%
[0544] Octocrylene ±0.4
[0545] 6% DHHB + 21.1 ± + 23% 9 2%
[0546] 4% EHT 0.5
[0547] 2.2 ± /
[0548] 10 / 2%
[0549] 0.0
[0550] 36.4 ± + 186% 11 10% BEMT 2%
[0551] 2.8
[0552] 5% + 46% Avobenzone 21.2 ±
[0553] 12 2%
[0554] + 5% 0.5
[0555] Octinoxate
[0556]
[0557] 10% 12.5 + 60%
[0558] 2%
[0559] Octocrylene ±0.3 6% DHHB + 24.1 ± + 40%
[0560] 2%
[0561] 4% EHT 0.5 1.5± / / 2%
[0562] 0.0 22.0 ± + 73% 10% BEMT 2%
[0563] 2.8 5% + 48% Avobenzone 21.5 ±
[0564] 2%
[0565] + 5% 1.7 Octinoxate
[0566] 10% 8.7 ± + 11%
[0567] 2%
[0568] Octocrylene 1.8 6% DHHB + 24.9 ± + 46%
[0569] 2%
[0570] 4% EHT 0.9
[0571] 1.6 ± / / 2%
[0572] 0.0 20.7 ± 10% BEMT 2%
[0573] 1.1 +63% 5%
[0574] Avobenzone 28.3 + 95%
[0575] 2%
[0576] + 5% ± 0.9 octinoxate
[0577] 10% 15.2
[0578] 2%
[0579] Octocrylene +95%
[0580] ± 0.2 6% DHHB + 27.1
[0581] 2%
[0582] 4% EHT + 58%
[0583] ± 1.1 / 2% 3.3 ± / 0.0 10% BEMT 2% 20.9 +64%
[0584] ± 1.0 2% 26.0 + 79% 5%
[0585] Avobenzone ± 1.3 + 5%
[0586] Octinoxate
[0587] 10% 2% 9.1 ± + 17% Octocrylene
[0588] 0.4
[0589]
[0590] 6% DHHB + 2% 23.6 + 38%
[0591] 29 4% EHT
[0592] ± 0.7
[0593] 34.1 + 168%
[0594] 30 10% BEMT
[0595] 1% ±0.7
[0596] 35.0 + 175%
[0597] 31 10% BEMT
[0598] 0.5% ±1.1
[0599] 5% 1% 17.0 + 17% 32 Avobenzone
[0600] + 5% ±2.0
[0601]
[0602] Octinoxate
[0603] 2-3 Evaluation of the SPF-boosting properties of inorganic UV filters
[0604] The following 3 compounds were tested in example 2-2:
[0605] 1 er Diester compound = diethyl(Z)-3-(4-hydroxyphenyl)pent-2-enedioate Diacid compound = (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid
[0606] 1 erCyclized compound = 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid, and representative of chemical subfamilies of formula (I) of the compounds of the invention, were evaluated in the same skincare formula, in combination with different inorganic UV filters (TiO2 or ZnO) to measure their SPF effect and their SPF-boosting effect (in combination with inorganic UV filters). The compounds are tested at a concentration of 2% by weight relative to the total weight of the composition.
[0607] Tested inorganic U filters (at 10%):
[0608] TiCh or Titanium Dioxide, sold in particular under the trade name "SP SOLAVEILXTP1 MBAL-PW-(MV) MB" by CRODA FRANCE SAS;
[0609] ZnO or Zinc Oxide, sold in particular under the trade name "ZINC OXIDE GOLD SEAL B" by UNIVAR FONTENAY.
[0610] The skincare formula used in this study is a water-in-oil emulsion with the following composition:
[0611] Table 4
[0612] Phase Ingrédients (nom INCI et référence commerciale) % en poids A1 DICAPRYLYL CARBONATE, STEARALKONIUM 6,0
[0613] HECTORITE, PROPYLENE CARBONATE, TOCOPHEROL
[0614] (COSMEDIA GEL CC)
[0615] A1 POLYGLYCERYL-4 4,0
[0616] DIISOSTEARATE / POLYHYDROXYSTEARATE / SEBACATE,
[0617]
[0618] CAPRYLIC / CAPRIC TRIGLYCERIDE, POLYGLYCERYL-3
[0619] OLEATE, DIISOSTEAROYL POLYGLYCERYL-3 DIMER DILINOLEATE, TOCOPHEROL, HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL (ISOLAN 17 MB)
[0620] A1 SORBITAN SESQUIOLEATE 1,6
[0621] A2 COCO-CAPRYLATE / CAPRATE (CETIOL LC MB) 27,6
[0622] A2 C15-19 ALKANE (EMOGREEN L15) 2,5
[0623] A3 FILTRE UV INORGANIQUE 10,0
[0624] A3 COCO-CAPRYLATE / CAPRATE (CETIOL LC MB) 7,5
[0625] A3 POLYHYDROXYSTEARIC ACID, CAPRYLIC / CAPRIC 0,3
[0626] TRIGLYCERIDE, ISOSTEARIC ACID, LECITHIN, POLYGLYCERYL-3 POLYRICINOLEATE (APPLECARE
[0627] PDS-300MB)
[0628] B1 WATER qs 100 B1 HYDROXYACETOPHENONE (SYMSAVE H) 0.3
[0629] B1 CHLORPHENESIN 0.27
[0630] B1 GLYCERIN 4.0
[0631] B1 PROPANEDIOL 4.0
[0632] B2 TROMETHAMINE 0.07
[0633] B3 or C COMPOSED OF FORMULA (I) Y
[0634]
[0635] The tested inorganic filters and respectively the compounds of formula (I) of the invention are incorporated into the skincare formula according to the following protocol:
[0636] The oily phase A containing the inorganic FUVs TiO2 or ZnO is prepared after passing the ZnO or TiO2 phase through the tri-cylinder (3 passes), then the oily phase is homogenized under ULTRATURRAX.
[0637] The aqueous phase B is heated to 70°C to solubilize the chlorphenesin, then stirred under a magnetic stir bar. The compounds of formula (I) are incorporated respectively as follows:
[0638] For 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid, it is added hot under a magnetic stir bar in the aqueous phase;
[0639] For (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid, the aqueous phase is allowed to cool and then the diacid is added to the aqueous phase;
[0640] Diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate, on the other hand, is added after the formation of the emulsion.
[0641] Phase B is added to phase A in a thin stream while stirring under ULTRATURRAX at 2000 rpm for 5 min. Phase C, containing diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate, is added after emulsification, while stirring under ULTRATURRAX at 2000 rpm for 2 min.
[0642] Formulas 33 and 34 are the control care formulas, with inorganic UV filters, but without the compound of the invention.
[0643] The other formulas are the care formulas comprising the combination of the different inorganic UV filters with each of the compounds of the invention tested at 2% and allow to measure the SPF booster effect of the compound of the invention.
[0644] The SPF assessment at T0 is carried out according to the protocol described in example 2-2 above.
[0645] The results are presented in Table 5 below, with:
[0646] 1 er Diester compound = diethyl (Z)-3-(4-hydroxyphenyl)pent-2-enedioate Diacid compound = (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid - 1 er Cyclized compound = 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0647] Table 5
[0648] SPF booster effect at T0 UV filters 1 er Expressed as a percentage
[0649] Compound 1 er SPF compound
[0650] Inorganic formulas Cyclized diacid augmentation compound T0
[0651] reference SPF diester with the compound of the invention versus without 2.7 ±
[0652] 33 ZnO at 10%
[0653] 0.0
[0654] 25.3 ±
[0655] 34 TiO2 at 10%
[0656] 0.4
[0657] 37.8 ± + 49% 35 TiO2 at 10% 2%
[0658] 1.1
[0659] 27.1 ± + 7% 36 TiO2 at 10% 2%
[0660] 1.0
[0661] 8.1 ± + 200% 37 ZnO at 10% 2%
[0662] 0.2
[0663] 6.8 ± + 152% 38 ZnO at 10% 2%
[0664] 0.2
[0665] 35.0 ± + 38% 39 TiO2 at 10% 2%
[0666] 1.6
[0667]
[0668] These results show that the compounds according to the invention have a low SPF as such but an SPF boosting effect in association with UV filters, whether organic UV filters (example 2-2) or inorganic UV filters (example 2-3).
[0669] This SPF boosting effect is obtained with different organic UV filters and inorganic UV filters from different families, and different combinations of organic UV filters, with SPF increases of at least 7% and up to 186% increase (formula 11) compared to the SPF of organic UVFs or inorganic UVFs without the compound of the invention.
[0670] In terms of SPF boosting effect on organic UV filters, the diacid compound appears to have the best performance (percentage increase in SPF), followed by cyclized compounds and then the diester compound. Regarding the boosting effect on inorganic UV filters, the opposite is observed, as the diester compound appears to have the best performance (percentage increase in SPF), followed by the diacid compound and then the cyclized compound, with even more pronounced effects (percentage increase in SPF > 150%) with ZnO, whose initial SPF is lower compared to that of TiCh.
[0671] It has been observed that the booster effect varies depending on the organic or inorganic UV filters used, thus allowing for the optimization of the organic and / or inorganic UV filter concentrations and the compound of the invention to obtain the desired SPF. The use of the compound of the invention therefore makes it possible to reduce the concentration of conventional UV filters, some of which are controversial, in favor of new compounds, while maintaining a very good SPF.
[0672] Example 3: Evaluation of the antioxidant properties of compounds of formula (I)
[0673] The antiradical activities of certain compounds of formula (I) according to the invention were determined by assaying 2,2-diphenyl-1-picrylhydrazyl (DPPH) to determine the EC50 values. The test began by adding 190 IL of DPPH solution (C = 200 IL) in ethanol to a well containing 10 IL L of potential antiradical solution in ethanol (concentrations from 800 to 1.5 IL M). The reaction was carried out in a BMG LABTECH VANTAstar system, and the disappearance of DPPH radicals was monitored at 520 nm every 2 minutes for 2 hours. Using different concentrations of potential antiradical solution yielded the EC50 value, which is the amount required to halve the initial population of DPPH radicals. BHA (butylated hydroxyanisole) was used as an antioxidant reference. The results are presented in the following table:
[0674] Table 6
[0675] EC50 molecule (nmol)
[0676] BHA (Butylated hydroxyanisole
[0677] (antioxidant reference) 7.0 + / - 1.0
[0678] (Z)-3-(4-hydroxy-3-methylphenyl)pent-2-enedioic acid
[0679] O^OH
[0680] 1 1
[0681] X^X*'
[0682] OH 4.1 + / - 0.4
[0683] diethyl (Z)-3-(4- hydroxyphenyl)pent-2- enedioate
[0684] X NS No activity (the 1st
[0685] XyX molecule has only one OH group in the para position) 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid
[0686] J l
[0687] > o*
[0688] 1.6 + / - 0.2
[0689] 2-(6,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid 2.4 + / - 0.1
[0690]
[0691] ( 1 0
[0692] ethyl 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetate
[0693] JÜ MO'
[0694] OH 13.5 + / -1.0
[0695] Ethyl 2-(7,8-dihydroxy-2-oxo-2H-chromen-4-yl)acetate
[0696] î ï
[0697] *** i6 * ! ' ! ^^
[0698] 3.8 + / - 0.4
[0699] (Z)-3-(3-hydroxy-2,4-dimethoxyphenyl)pent-2-enedioic acid
[0700] K H0OX yJ
[0701] 10.5 + / - 0.6
[0702]
[0703] NS: not significant
[0704] These results show that antioxidant activity is correlated with the presence of at least two radicals (R 3 to R 7 on formula (I)) substituted (the compound with only one OH in the para position has no activity). The highest activity (lowest EC50) is obtained for the two-ring compounds of formula (IA) according to the invention.
Claims
1. CLAIMS 1. Cosmetic composition comprising, in a physiologically acceptable medium: (i) A compound of the following formula (I): in which R 1 and R 2 independently represent H or an optionally substituted C1-C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-C6 alkyl), and R 3 to R 7 independently represents H, a halogen, an OH group, an NO2 group, an N3 group, or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH, or N(Ci-Ce alkyl), or R 2 and R 3taken together they form a simple bond. provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H, And (ii) One or more organic UV filter(s) selected from organic UV filters, inorganic UV filters, and mixtures thereof.
2. Composition according to claim 1, characterized in that the organic UV filters are selected from the group consisting of: cinnamyl derivatives; salicylic derivatives; dibenzoylmethane derivatives; benzophenone derivatives; α-3,p-diphenylacrylate derivatives; triazine derivatives; anthranilates; camphor derivatives; benzotriazole derivatives; benzalmalonate derivatives; imidazolines; p-aminobenzoic acid (PABA) derivatives; benzoxazole derivatives; α-alkylstyrene derivative dimers; 4,4-diarylbutadiene; merocyanine derivatives, merocyanins, phenyl benzimidazole compounds, Diethyl amino Hydroxy benzoyl Hexyl Benzoate (DHHB), Terephthalylidene Dicamphor Sulfonic Acid (TDSA), and mixtures thereof, in particular cinnamic derivatives; p,p-diphenyl acrylate derivatives;triazine derivatives, phenyl benzotriazole derivatives, benzophenone derivatives, dibenzoylmethane derivatives, and mixtures thereof, and preferably Butyl Methoxydibenzoylmethane (BMDBM), Ethylhexyl Methoxycinnamate or Octyl Methoxycinnamate or Octinoxate, Octocrylene, Diethyl amino Hydroxybenzoyl Hexyl Benzoate (DHHB), Ethyl Hexyl triazone (EHT), Bisethylhexyloxyphenol methoxyphenyl triazine (BEMT), and mixtures thereof, and inorganic UV filters are selected from titanium oxides, zinc oxides, and mixtures thereof, preferably titanium oxides, zinc oxides, and mixtures thereof.
3. Composition according to claim 1 or claim 2, characterized in that the content of compound of formula (I) ranges from 0.3 to 20% by weight, in particular from 0.5 to 10% by weight relative to the total weight of the composition.
4. Composition according to any one of claims 1 to 3, characterized in that the total content of organic and / or inorganic UV filters ranges from 0.3 to 20% by weight, in particular from 0.5 to 15% by weight relative to the total weight of the composition.
5. Cosmetic composition comprising, in a physiologically acceptable medium: - at least one compound of the following formula (I) in which R 1 and R 2 independently represent H or an optionally substituted C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and R 3 to R 7represents independently of each other H, a halogen, an OH group, an NO2 group, an N3 group or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH or N(Ci-Ce alkyl), Or R 2 and R 3 taken together form a simple link, provided that when one of R 3 to R 7 represents an OH group and the others represent H, at least one of R 1 and R 2 is different from H, and The compound with formula (I) is not one of the following compounds: an additional cosmetic ingredient.
6. Cosmetic composition according to claim 5, wherein R 2 and R 3 taken together form a simple bond, the R substitute 1is preferably chosen from H and an alkyl group in C1-C20, and two or three substituents from R 4 to R 7 are not H and preferably chosen from OH, an alkoxy in Ci-Ce, and an alkyl in Ci-Ce, the remaining substituents from R 4 to R 7 representing H.
7. Cosmetic composition according to claim 5, wherein R 1 and R 2 both represent H, and two or three substituents from R 3 to R 7 are preferably chosen from OH, an alkoxy in Ci-Ce, or an alkyl in Ci-Ce, the substituents remaining from R 3 to R 7 representing H.
8. Cosmetic composition according to claim 5, wherein R 1 and R 2 both independently represent an alkyl in Ci-Ce, and at least one among R 3 to R 7 is preferably chosen from OH, an alkoxy in Ci-Ce, or an alkyl in Ci-Ce, the substituents remaining from R 3 to R7 representing H.
9. A cosmetic composition according to claim 5, wherein the compound of formula (I) is selected from the group consisting of:
10. Composition according to any one of claims 1 to 9, characterized in that it is a skincare composition, a sun care composition or a makeup composition for the skin and / or lips, in particular a skincare composition or a foundation.
11. Non-therapeutic cosmetic process for the care and / or makeup of healthy skin and / or healthy lips, comprising the application to said skin and / or lips of a composition as defined in any one of claims 1 to 10, in particular for improving the evenness of the complexion and / or reducing the signs of skin aging.
12. Compound of the following formula (I): R s ( |) in which R 1 and R 2 independently represent H or an optionally substituted C20 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally replaced by O, C(O), NH, or N(Ci-Ce alkyl), and R 3 to R 7 represents independently of each other H, a halogen, an OH group, an NO2 group, an N3 group or an optionally substituted C1-C12 aliphatic chain, wherein one or more, preferably one to four, methylene units of the aliphatic chain are optionally and independently replaced by O, C(O), NH or N(Ci-Ce alkyl), Or R 2 and R 3 taken together they form a simple bond. provided that when one among R 3 to R 7 represents an OH group and the others represent H, at least one of R 1and R 2 is different from H, and The compound with formula (I) is not one of the following compounds:
13. Formula compound (I) as defined in claim 12, wherein R 2 and R 3 taken together form a simple bond, the R substitute 1 is preferably chosen from H and an alkyl group in C1-C20, and two or three substituents from R 4 to R 7 are not H and preferably chosen from OH, an alkoxy in Ci-Ce, and an alkyl in Ci-Ce, the remaining substituents from R 4 to R 7 representing H.
14. Formula compound (I) as defined in claim 12, wherein R 1 and R 2 both represent H, and two or three substituents from R 3 to R 7 are preferably chosen from OH, an alkoxy in Ci-Ce, or an alkyl in Ci-Ce, the substituents remaining from R 3to R 7 representing H.
15. Formula compound (I) as defined in claim 12, wherein R 1 and R 2 both independently represent an alkyl in Ci-Ce, and at least one among R 3 to R 7 is preferably chosen from OH, an alkoxy in Ci-Ce, or an alkyl in Ci-Ce, the substituents remaining from R 3 to R 7 representing H.
16. Formula compound (I) as defined in claim 12, selected from the group consisting of:
17. Non-therapeutic use of a compound of formula (I) as defined in any one of claims 12 to 16 or of a compound of formula (I) as defined in claim 1, in a cosmetic composition comprising one or more organic and / or inorganic UV filters, as an SPF booster agent.
18. A compound of formula (I) as defined in any one of claims 12 to 16, or a composition as defined in any one of claims 1 to 10, for use in the prevention and / or treatment of the adverse effects of ultraviolet radiation on the skin and / or lips.
